Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab Monotherapy and Combination With Venetoclax in R/R CLL/SLL
NCT05091424Phase 1Recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Primary completion
- Feb 2031
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, open-label trial of mosunetuzumab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (3 arms), sponsored by Roche. Primary endpoints: Rate of Dose-Limiting Toxicities up to 3 months and Objective Response Rate During Dose Expansion Phase. Started Mar 2022; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05091424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091424.